Linda Mileshkin, ESMO 2019 – Phase III OUTBACK trial in cervical cancer
We joined Linda Mileshkin (Peter MacCallum Cancer Centre) following her presentation at ESMO 2019 to discuss the disparities of starting adjuvant chemotherapy for locally advanced cervix cancer in the international, academic, randomised, phase III OUTBACK trial.
1. Could you tell us a little about the OUTBACK trial and its findings? (0:06)
2. What was the impact of the delayed start of adjuvant therapy on clinical outcomes? (1:31)
3. What can be done to minimise these disparities? (2:01)
4. What are the key take home messages of your presentation? (2:40)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosure: Linda Mileshkin has nothing to disclose in relation to this video.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Gynaecological Cancers
Paul DiSilvestro, ESMO 2022: SOLO1/GOG-3004 trial – Olaparib for the treatment of advanced ovarian cancer – Overall survival findings at 7 years
The Phase III SOLO1/GOG-3004 trial (NCT01844986), investigated maintenance olaparib, which provided sustained benefit beyond the end of treatment in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. Prof. Paul DiSilvestro (Brown University, Providence, RI, USA) joins touchONCOLOGY to discuss the efficacy and safety of maintenance olaparib, and overall survival findings at 7 years. […]
Keiichi Fujiwara, ESMO 2022: Phase 3 GOTIC-002 LUFT study results – Chemotherapy with tegafur-uracil for locally advanced cervical cancer
Maintenance chemotherapy with oral tegafur-uracil (UFT) after surgery has been shown to prolong survival in lung, breast, gastric and colon cancer. Dr Keiichi Fujiwara (Saitama Medical University International Medical Centre, Saitama, Japan) joins touchONCOLOGY to discuss the phase 3 GOTIC-002 LUFT study results, investigating the efficacy of maintenance chemotherapy using UFT following concurrent chemoradiotherapy for […]
Keiichi Fujiwara, ESMO 2022: Clinical trial highlights in gynaecological cancer
Dr Keiichi Fujiwara joins touchONCOLOGY to discuss his thoughts on the latest clinical trial highlights at European Society for Medical Oncology (ESMO) 2022 in gynaecological cancers, specifically the GOTIC-002 LUFT study. Watch Dr Keiichi Fujiwara’s interview at ESMO 2022, on the Phase 3 GOTIC-002 LUFT study results – chemotherapy with tegafur-uracil for locally advanced cervical […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!